Early prediction of response to 40 kDa peginterferon alfa-2A (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC): Peter Ferenci, University of Vienna, Wein Austria; Mitchell L Shiffman, Medical College of Virginia, Richmond, VA; Michael W Fried, University of North Carolina, Chapel Hill, NC; Mark S Sulkowski, Johns Hopkins Center for Viral Hepatitis, Baltimore, MD; Dieter Haeussinger, University of Duesseldorf, Duesseldorf Germany; Jean-Pierre Zarski, CHU de Grenoble, Grenoble France; Fernando Goncales Jr., University of Campinas, Campinas Spain; Donald M Jensen, Rush-Presbuterian St Luke's Hospital, Chicago, IL; Ferrucio Bonino, Azienda Ospedaliera Univ Pisana, Pisa Italy; Daniel Dhumeaux, Hôpital Henri Mondor, Creteil France; Steven Blotner, Joseph Hoffman, Joseph Oliveto, Hoffmann-La Roche, Nutley, NJ